Jennifer A. Macdiarmid

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Therapeutic potential of synthetic microRNA mimics based on the miR-15/107 consensus sequence.

Therapeutic potential of synthetic microRNA mimics based on the miR-15/107 consensus sequence.

Journal: Cancer gene therapy

Published: September 15, 2024

Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate.

Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate.

Journal: The oncologist

Published: April 12, 2024

A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor.

A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor.

Journal: Targeted oncology

Published: March 06, 2024

Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells.

Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 20, 2023

Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern.

Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern.

Journal: Frontiers in immunology

Published: September 07, 2022

Bacterial minicells to the rescue: cyto-Immunotherapy for the treatment of late stage cancers with minimal to no toxicity.

Bacterial minicells to the rescue: cyto-Immunotherapy for the treatment of late stage cancers with minimal to no toxicity.

Journal: Microbial biotechnology

Published: October 06, 2021

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma.

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma.

Journal: Molecular medicine (Cambridge, Mass.)

Published: August 09, 2020

RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.

RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.

Journal: Thyroid : official journal of the American Thyroid Association

Published: April 02, 2019

Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells.

Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells.

Journal: Cancer cell

Published: September 13, 2018

Translational applications of microRNAs in cancer, and therapeutic implications.

Translational applications of microRNAs in cancer, and therapeutic implications.

Journal: Non-coding RNA research

Published: October 18, 2017

Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma.

Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma.

Journal: Molecular cancer therapeutics

Published: August 04, 2017

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

Journal: The Lancet. Oncology

Published: May 22, 2017

Showing 1-12 of 23

Last Updated: 09/26/2026